TG Therapeutics Stock Price

0.37 (0.91%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
TG Therapeutics Inc TGTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.37 0.91% 41.09 18:26:05
Open Price Low Price High Price Close Price Prev Close
41.02 40.15 42.1299 41.09 40.72
Bid Price Ask Price Spread News
41.10 41.98 0.88 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
11,985 1,187,692 $ 41.16 $ 48,885,255 2,770,167 10.83 - 56.74
Last Trade Time Type Quantity Stock Price Currency
19:54:48 1 $ 41.22 USD

TG Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 5.66B 137.81M 110.44M $ 152.00k $ - -1.95 -23.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

TG Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TGTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week45.1549.387938.71542.942,321,445-4.06-8.99%
1 Month44.3550.0038.71545.051,519,676-3.26-7.35%
3 Months46.8156.5038.44546.731,486,445-5.72-12.22%
6 Months27.2756.7424.9343.811,732,29913.8250.68%
1 Year12.5656.7410.8331.651,855,99128.53227.15%
3 Years14.3556.743.3217.311,655,61526.74186.34%
5 Years10.2056.743.3215.211,440,49830.89302.84%

TG Therapeutics Description

TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.

Your Recent History
TG Therape..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.